ATE344029T1 - Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern - Google Patents
Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmernInfo
- Publication number
- ATE344029T1 ATE344029T1 AT02713070T AT02713070T ATE344029T1 AT E344029 T1 ATE344029 T1 AT E344029T1 AT 02713070 T AT02713070 T AT 02713070T AT 02713070 T AT02713070 T AT 02713070T AT E344029 T1 ATE344029 T1 AT E344029T1
- Authority
- AT
- Austria
- Prior art keywords
- diabetes
- dipeptidyl peptidase
- inhibitors
- treating type
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0109146.1A GB0109146D0 (en) | 2001-04-11 | 2001-04-11 | Treatment of type 2 diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE344029T1 true ATE344029T1 (de) | 2006-11-15 |
Family
ID=9912727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02713070T ATE344029T1 (de) | 2001-04-11 | 2002-04-10 | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040209891A1 (de) |
EP (1) | EP1377278B1 (de) |
JP (1) | JP2004525179A (de) |
KR (1) | KR20040025915A (de) |
CN (1) | CN1248683C (de) |
AT (1) | ATE344029T1 (de) |
AU (1) | AU2002244860B2 (de) |
CA (1) | CA2443229A1 (de) |
CZ (1) | CZ20032927A3 (de) |
DE (1) | DE60215787T2 (de) |
GB (1) | GB0109146D0 (de) |
HK (1) | HK1059213A1 (de) |
HU (1) | HUP0303876A3 (de) |
IL (1) | IL157821A0 (de) |
MX (1) | MXPA03009224A (de) |
NO (1) | NO20034549D0 (de) |
NZ (1) | NZ528172A (de) |
PL (1) | PL366633A1 (de) |
RU (1) | RU2328283C2 (de) |
UA (1) | UA76452C2 (de) |
WO (1) | WO2002083109A1 (de) |
ZA (1) | ZA200307156B (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2450722A1 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
GB0125445D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
AU2002952946A0 (en) * | 2002-11-27 | 2002-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
JP4887139B2 (ja) | 2003-03-25 | 2012-02-29 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
RU2006107553A (ru) | 2003-08-13 | 2007-09-20 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 4-пиримидона и их применение в качестве ингибиторов пептидилпептидаз |
EP1699777B1 (de) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidylpeptidase-hemmer |
KR20180050427A (ko) | 2003-11-17 | 2018-05-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
US20070149451A1 (en) * | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
RS57561B1 (sr) | 2004-01-20 | 2018-10-31 | Novartis Ag | Formulacija dobijena direktnom kompresijom i proces za njeno dobijanje |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
NZ549716A (en) | 2004-03-15 | 2010-04-30 | Takeda Pharmaceutical | Pyrimidin-dione derivatives as dipeptidyl peptidase inhibitors |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
ATE553077T1 (de) * | 2004-07-23 | 2012-04-15 | Nuada Llc | Peptidaseinhibitoren |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
US7553861B2 (en) | 2005-04-22 | 2009-06-30 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
CN101232873A (zh) * | 2005-08-11 | 2008-07-30 | 霍夫曼-拉罗奇有限公司 | 含有dpp-iv抑制剂的药物组合物 |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2146210A1 (de) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden |
FR2938999B1 (fr) * | 2008-11-24 | 2011-07-01 | Oreal | Procede de preparation d'un parfum au sein d'un systeme comportant une pluralite de terminaux interactifs de formulation de parfums et un serveur agence pour echanger des donnees avec la pluralite de terminaux |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
ATE482717T1 (de) * | 1999-02-10 | 2010-10-15 | Curis Inc | Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten |
GB9906714D0 (en) * | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
AU1916401A (en) * | 1999-11-12 | 2001-06-06 | Guilford Pharmaceuticals Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
EP2055302B1 (de) * | 2000-03-31 | 2014-09-10 | Royalty Pharma Collection Trust | Verfahren zur Verbesserung der Langerhans'-Inselsignalisierung in Diabetes mellitus und zu dessen Prävention |
GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
-
2001
- 2001-04-11 GB GBGB0109146.1A patent/GB0109146D0/en not_active Ceased
-
2002
- 2002-04-10 IL IL15782102A patent/IL157821A0/xx unknown
- 2002-04-10 HU HU0303876A patent/HUP0303876A3/hu unknown
- 2002-04-10 CA CA002443229A patent/CA2443229A1/en not_active Abandoned
- 2002-04-10 AU AU2002244860A patent/AU2002244860B2/en not_active Ceased
- 2002-04-10 NZ NZ528172A patent/NZ528172A/en unknown
- 2002-04-10 KR KR10-2003-7013350A patent/KR20040025915A/ko not_active Application Discontinuation
- 2002-04-10 EP EP02713070A patent/EP1377278B1/de not_active Expired - Lifetime
- 2002-04-10 MX MXPA03009224A patent/MXPA03009224A/es active IP Right Grant
- 2002-04-10 PL PL02366633A patent/PL366633A1/xx unknown
- 2002-04-10 JP JP2002580913A patent/JP2004525179A/ja not_active Withdrawn
- 2002-04-10 US US10/474,676 patent/US20040209891A1/en not_active Abandoned
- 2002-04-10 DE DE60215787T patent/DE60215787T2/de not_active Expired - Fee Related
- 2002-04-10 AT AT02713070T patent/ATE344029T1/de not_active IP Right Cessation
- 2002-04-10 WO PCT/GB2002/001674 patent/WO2002083109A1/en active IP Right Grant
- 2002-04-10 RU RU2003132687/14A patent/RU2328283C2/ru not_active IP Right Cessation
- 2002-04-10 CN CNB028080955A patent/CN1248683C/zh not_active Expired - Fee Related
- 2002-04-10 CZ CZ20032927A patent/CZ20032927A3/cs unknown
- 2002-10-04 UA UA2003109184A patent/UA76452C2/uk unknown
-
2003
- 2003-09-12 ZA ZA200307156A patent/ZA200307156B/en unknown
- 2003-10-09 NO NO20034549A patent/NO20034549D0/no not_active Application Discontinuation
-
2004
- 2004-03-11 HK HK04101781A patent/HK1059213A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2328283C2 (ru) | 2008-07-10 |
RU2003132687A (ru) | 2005-04-10 |
NZ528172A (en) | 2004-09-24 |
KR20040025915A (ko) | 2004-03-26 |
CN1501796A (zh) | 2004-06-02 |
HK1059213A1 (en) | 2004-06-25 |
NO20034549L (no) | 2003-10-09 |
IL157821A0 (en) | 2004-03-28 |
EP1377278B1 (de) | 2006-11-02 |
DE60215787T2 (de) | 2007-08-30 |
HUP0303876A2 (hu) | 2004-03-01 |
CN1248683C (zh) | 2006-04-05 |
HUP0303876A3 (en) | 2005-06-28 |
AU2002244860B2 (en) | 2006-11-16 |
JP2004525179A (ja) | 2004-08-19 |
EP1377278A1 (de) | 2004-01-07 |
MXPA03009224A (es) | 2004-01-29 |
NO20034549D0 (no) | 2003-10-09 |
WO2002083109A1 (en) | 2002-10-24 |
GB0109146D0 (en) | 2001-05-30 |
CZ20032927A3 (cs) | 2004-06-16 |
PL366633A1 (en) | 2005-02-07 |
ZA200307156B (en) | 2004-06-04 |
CA2443229A1 (en) | 2002-10-24 |
DE60215787D1 (de) | 2006-12-14 |
UA76452C2 (en) | 2006-08-15 |
US20040209891A1 (en) | 2004-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE344029T1 (de) | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern | |
DE602004027936D1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
SE0301886D0 (sv) | New use V | |
SE0301882D0 (sv) | New use I | |
EE9900481A (et) | Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
BR0214309A (pt) | Derivados aril-1,4-pirazina substituìdos | |
WO2004017920A3 (en) | Novel biphenyl and biphenyl-like cannabinoids | |
CY1106283T1 (el) | Κινολινυλ-πυρρολοπυραζολες | |
EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
CY1109013T1 (el) | Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν | |
MXPA03006224A (es) | Inhibidores de cruzipaina y otras proteasas de cisteina. | |
BRPI0411324A (pt) | composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes | |
WO2004110392A3 (en) | Compositions and methods for treating coronavirus infection and sars | |
SE0201940D0 (sv) | New combination II | |
DK1237562T3 (da) | Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme | |
DE60334094D1 (de) | Verwendung von pleuromutilinen zur behandlung von erkrankungen, die durch helicobacter pylori verursacht werden | |
ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
ATE504302T1 (de) | Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten | |
RS50681B (sr) | Kombinacija taksana i ciklin-zavisne kinaze | |
WO2002057246A3 (en) | Inhibitors of cruzipain and other cysteine proteases | |
DE50309647D1 (de) | Ng fibrotischer erkrankungen | |
SE0301884D0 (sv) | New use III | |
FR2839450B1 (fr) | Preparation medicamenteuse notamment pour le traitement des hernies discales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |